



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/600,266	06/20/2003	Fumitoshi Asai	03337C/HG	7488

1933 7590 03/06/2006

FRISHAUF, HOLTZ, GOODMAN & CHICK, PC  
220 Fifth Avenue  
16TH Floor  
NEW YORK, NY 10001-7708

EXAMINER
----------

KWON, BRIAN YONG S

ART UNIT	PAPER NUMBER
----------	--------------

1614

DATE MAILED: 03/06/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/600,266	ASAI ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Brian S. Kwon	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 09 December 2005.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) 6-14 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-5 and 15-19 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)             | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

## **DETAILED ACTION**

### ***Status of Application***

1. By Amendment filed December 09, 2005, claim 1 has been amended and claims 15-19 has been newly added.
2. Claims 1-5 and 15-19 are currently pending for prosecution on the merits.

### ***Summary of Action***

3. The rejection of the claims 1-3 under 35 U.S.C. 102(e) as being anticipated by Ogletree (US 6509348) is not maintained in light of the amendment.
4. The rejection of the claims 4 and 5 under 35 U.S.C. 103(a) as being unpatentable over Ogletree (US 6509348) in view of Koike et al. (US 5288726) is not maintained in light of the amendment.
5. Applicant's amendment requiring "there is no thromboxane A2 receptor antagonist" in claims 1-5 and "consisting essentially of" in claims 15-19 necessitates a new ground of rejection(s) in this Office Action.

### ***Response to Arguments***

6. Applicant's arguments/Declaration with respect to claims 1-5 have been considered but are moot in view of the new ground(s) of rejection.

### ***New Matter***

7. The amendment filed December 09, 2005 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not

Art Unit: 1614

supported by the original disclosure is as follows: “there is no thromboxane A2 receptor antagonist”.

Applicant is required to cancel the new matter in the reply to this Office Action.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 1-5 and 15-19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims in this application introduce a negative limitation as discussed in preceding comments, namely “there is no thromboxane A2 receptor antagonist”. The examiner determines that when all evidences in the original disclosure are considered and carefully reviewed, the newly amended claims fail to find support in the original specification.

The specification only positively states about the boundaries of the claim. There is no express statement about the negative limitation that can be found in the specification. Thus, the exclusion of said elements implies the inclusion of all other elements not expressly excluded, clearly illustrating that such negative limitations do, in fact, introduce new matter. The negative limitation recited in the present claims, which did not appear in the specification filed, introduces new concepts and violate the description requirement of the first paragraph of 35 USC 112.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 4 and 5 rejected under 35 U.S.C. 103(a) as being unpatentable over Ogletree (US 6509348) in view of Bernat et al. (US 5989578), and further in view of Koike et al. (US 5288726).

Art Unit: 1614

Ogletree teaches a pharmaceutical composition comprising ADP receptor blocking antiplatelet drug (i.e., CS-747 which is 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine, clopidogrel and ticlopidine) or pharmaceutically acceptable salts thereof in combination with thromboxane A2 receptor antagonist and aspirin, wherein the ratio of said ADP receptor blocking antiplatelet drug and aspirin is within the range from about 50:1 to about 0.51, preferably from about 25:1 to about 1:1 (see column 4, lines 18-30 and 38-42; column 31, lines 32-37). Ogletree discloses CS-747 as the functional equivalent to other known ADP receptor blocking antiplatelet drug such as clopidogrel and ticlopidine.

Bernat teaches a pharmaceutical composition comprising ADP receptor blocking antiplatelet drug (i.e., clopidogrel or ticlopidogrel) in combination with aspirin.

Koike teaches compounds represented by formula (I) including 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine, wherein said compounds are prepared in pharmaceutically salts thereof including maleate and hydrochloride (abstract; column 13, lines 43-63; column 22, line 19 and Example 23).

The teaching of Ogletree differs from the claimed invention in (i) the preparation of said composition in absence of thromboxane A2 receptor antagonist and (ii) in the specific salt form, namely hydrochloride or maleate. To incorporate teaching of Ogletree, would have been obvious in view of Bernat who teaches the routine knowledge in preparing combination of ADP receptor blocking antiplatelet drug and aspirin in absence of thromboxane A2 receptor antagonist and further in view of Koike who teaches the preparation of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine in the form of maleate and hydrochloride salt.

Art Unit: 1614

Above references in combination make clear that making combinations of three components, (a) ADP-receptor blocking antiplatelet drug, (b) tromboxane A2 receptor antagonis and (c) aspirin or combination of two components, (a) ADP-receptor blocking antiplatelet drug and (c) aspirin is well known in the art. Above references in combination also make clear that the substitution of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine for other known ADP-receptor blocking antiplatelet drug (i.e., clopidogrel and ticlopidogrel) is well within the skill of the artisan. Thus, one would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities), and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

In addition, one having ordinary skilled in the art would have been motivated to select the claimed compounds in maleate or hydrochloride salt with reasonable expectation of success that preparation of said composition in maleate and hydrochloride salt form would not significantly alter the analogous properties of compound of the reference due to close structural similarity of the compounds.

### *Conclusion*

10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Art Unit: 1614

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

11. No Claim is allowed.


12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (571) 272-0951. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Brian Kwon  
Patent Examiner  
AU 1614



  
CHRISTOPHER S. F. LOW  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600